Healthy, Influenza
Conditions
Keywords
Influenza A, pandemic, vaccine, immunogenicity, Virus, H5N1
Brief summary
The safety and tolerability of the pandemic A/H5N1 virosomal vaccine formulated with or without the 3rd generation ISCOM™ adjuvant for parenteral administration will be investigated locally and systemically and by using haematological, biochemical and immunological screening tests. The immunogenicity of the H5N1 vaccine will be assessed through the induction of local and systemic antibody and cellular immune responses. In a pandemic situation, an important aspect is the rapidity of the immune response to the H5N1 vaccine so the detailed kinetics of the immune response will be investigated. The capacity of the vaccine to elicit long lasting immunity and cross reactive immunity to H5 viruses will also be evaluated. Furthermore, the quality of the immune response induced by the vaccine will be studied. The vaccine will be administered as twice the normal human dose (30μg HA) with and without adjuvant, and in a dose sparing manor of half (7.5μg HA) and one tenth (1.5μg HA) of the normal human dose with adjuvant. Sixty subjects will receive two doses of virosomal H5N1 influenza vaccine (separated by 21 ± 4 days) by intramuscular injection into the deltoid muscle. Escalating doses will be separated by a period of one week. Four groups each containing 15 subjects will receive two doses of the pandemic virosomal A/H5N1 influenza vaccine containing: Group 1 30µg HA IM, Group 2 1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ IM, Group 3 7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ IM, Group 4 30µg HA adjuvanted with 50µg 3rd generation ISCOM™ IM.
Interventions
BIOLOGICALInfluenza vaccine
Influenza virus strain: avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14
Sponsors
Haukeland University Hospital
European Commission
Rebecca Cox
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy volunteers (as concluded from the medical history, physical examination, and clinical judgment) aged 19 to 50 years old * Females using a reliable method of contraception (from 4 weeks prior to the first vaccination until 4 weeks after the second vaccination) and a negative urine pregnancy test will be required before administration of each dose of vaccine * Signed informed consent * Subjects able to understand and comply with the study protocol and complete the Adverse Event Form * Subjects able to attend the scheduled visits * Subjects with normal pre-screening values. If a subjects prescreening samples lie outside the reference values he/she will only be included in the study based upon the medical evaluation of the clinical investigator
Exclusion criteria
* Persons with a history of anaphylaxis or serious reactions to any vaccine * Persons with known hypersensitivity to any of the vaccine components * Persons who have had a temperature \>38oC during the previous 72 hours * Persons who have had an acute respiratory infection during the last 7 days * Women who are pregnant or breast-feeding * Persons with chronic illness at any stage that could interfere with trial conduct or compliance * Persons who have received blood products or immunoglobulins parenterally during the previous 3 months * Persons who have been vaccinated with any vaccine during the 4 weeks preceding the first trial vaccination * Persons with known or suspected immunosuppressive disease or who use systemic immunosuppressive drugs * Persons taking immunostimulant therapy * Persons involved in another clinical trial during the last month. * Suspected non-compliance
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Solicted Adverse Events | three months | The primary endpoints of the trial are the local and systemic adverse events and tolerability of parenterally administered virosomal H5N1 influenza vaccine with or without 3rd generation ISCOM™ adjuvant. |
| Adverse Events | 42 days | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity of a Non-adjuvanted and 3rd Generation ISCOM™ Adjuvanted Virosomal H5N1 Influenza Vaccine | one year | Number of participants with haemagglutination inhibition tigers \>= 32 at the long term time point (1 year post vaccination). |
Countries
Norway
Participant flow
Recruitment details
Haukeland University hospital recrutiment in 2009
Pre-assignment details
Haelthy person were randomly assigned to one of 4 vaccine groups
Participants by arm
| Arm | Count |
|---|---|
| 30µg HA Vaccine 30µg HA vaccine Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14 | 15 |
| 1.5µg HA Adjuvanted 1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14 | 15 |
| 7.5µg HA Adjuvanted 7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14 | 15 |
| 30µg HA Adjuvanted 30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
Influenza vaccine: Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14 | 15 |
| Total | 60 |
Baseline characteristics
| Characteristic | 1.5µg HA Adjuvanted | 7.5µg HA Adjuvanted | 30µg HA Vaccine | 30µg HA Adjuvanted | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 15 Participants | 15 Participants | 15 Participants | 15 Participants | 60 Participants |
| Age, Continuous | 29 years | 31 years | 32 years | 31 years | 31 years |
| Region of Enrollment Norway | 15 participants | 15 participants | 15 participants | 15 participants | 60 participants |
| Sex: Female, Male Female | 10 Participants | 8 Participants | 9 Participants | 11 Participants | 38 Participants |
| Sex: Female, Male Male | 5 Participants | 7 Participants | 6 Participants | 4 Participants | 22 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 8 / 15 | 13 / 15 | 12 / 15 | 13 / 15 |
| serious Total, serious adverse events | 0 / 15 | 0 / 15 | 0 / 15 | 0 / 15 |
Outcome results
Primary
Adverse Events
Time frame: 42 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 30µg HA Vaccine | Adverse Events | 0 participants |
| 1.5µg HA Adjuvanted | Adverse Events | 0 participants |
| 7.5µg HA Adjuvanted | Adverse Events | 0 participants |
| 30µg HA Adjuvanted | Adverse Events | 0 participants |
Primary
Solicted Adverse Events
The primary endpoints of the trial are the local and systemic adverse events and tolerability of parenterally administered virosomal H5N1 influenza vaccine with or without 3rd generation ISCOM™ adjuvant.
Time frame: three months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 30µg HA Vaccine | Solicted Adverse Events | 8 participants |
| 1.5µg HA Adjuvanted | Solicted Adverse Events | 12 participants |
| 7.5µg HA Adjuvanted | Solicted Adverse Events | 13 participants |
| 30µg HA Adjuvanted | Solicted Adverse Events | 14 participants |
Secondary
Immunogenicity of a Non-adjuvanted and 3rd Generation ISCOM™ Adjuvanted Virosomal H5N1 Influenza Vaccine
Number of participants with haemagglutination inhibition tigers \>= 32 at the long term time point (1 year post vaccination).
Time frame: one year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 30µg HA Vaccine | Immunogenicity of a Non-adjuvanted and 3rd Generation ISCOM™ Adjuvanted Virosomal H5N1 Influenza Vaccine | 0 participants |
| 1.5µg HA Adjuvanted | Immunogenicity of a Non-adjuvanted and 3rd Generation ISCOM™ Adjuvanted Virosomal H5N1 Influenza Vaccine | 0 participants |
| 7.5µg HA Adjuvanted | Immunogenicity of a Non-adjuvanted and 3rd Generation ISCOM™ Adjuvanted Virosomal H5N1 Influenza Vaccine | 1 participants |
| 30µg HA Adjuvanted | Immunogenicity of a Non-adjuvanted and 3rd Generation ISCOM™ Adjuvanted Virosomal H5N1 Influenza Vaccine | 2 participants |